Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.45 USD | -5.82% |
|
+5.37% | +51.42% |
May. 14 | Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | North American Morning Briefing : More Earnings -2- | DJ |
Business Summary
Number of employees: 60
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 18-03-31 | |
Kristina Masson
FOU | Founder | 44 | 18-02-28 |
Director of Finance/CFO | 53 | 22-03-31 | |
Monica Phadnis
CTO | Chief Tech/Sci/R&D Officer | - | - |
Bruce Close
CMP | Compliance Officer | - | - |
Karl Hsu
CTO | Chief Tech/Sci/R&D Officer | - | Jan. 02 |
Chief Tech/Sci/R&D Officer | - | Jan. 02 | |
Eric Devroe
COO | Chief Operating Officer | 46 | 22-07-31 |
Adam Levy
IRC | Investor Relations Contact | - | 23-07-19 |
Comptroller/Controller/Auditor | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | Feb. 07 | |
Sharon Shacham
BRD | Director/Board Member | 53 | 20-09-30 |
Chief Executive Officer | 62 | 18-03-31 | |
Michael Tomsicek
BRD | Director/Board Member | 58 | 22-09-30 |
Charles Baum
BRD | Director/Board Member | 65 | 23-06-21 |
Derek DiRocco
BRD | Director/Board Member | 43 | 21-10-31 |
Kristina Masson
FOU | Founder | 44 | 18-02-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 30,876,932 | 18,439,513 ( 59.72 %) | 0 | 59.72 % |
Company contact information
![address Acrivon Therapeutics, Inc.(ACRV)](https://cdn.zonebourse.com/static/address/146590781.png)
Sector
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.42% | 230M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- ACRV Stock
- Company Acrivon Therapeutics, Inc.